Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...
Herpes Simplex Encephalitis: Flair axial MRIs. Note the abnormal (bright) signal in both temporal lobes (left image). Also note the involvement of the insula on the right side (middle image) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback